BamSEC and AlphaSense Join Forces
Learn More

Coherus BioSciences Inc.

NASDAQ: CHRS    
Share price (12/20/24): $1.52    
Market cap (12/20/24): $175 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.5
from 10-Q 39 pages [***] Certain Information in This Exhibit Has Been Omitted Because It Is Permitted to Be Omitted by Applicable Regulatory Guidance
12/34/56
EX-10.4
from 10-Q 14 pages [***] Certain Information in This Exhibit Has Been Omitted Because It Is Permitted to Be Omitted by Applicable Regulatory Guidance
12/34/56
EX-10.3
from 10-Q 29 pages Article 2. Definitions and Construction
12/34/56
EX-10.2
from 8-K/A 64 pages [***] Certain Information in This Exhibit Has Been Omitted Because It Is Permitted to Be Omitted by Applicable Regulatory Guidance. ​
12/34/56
EX-10.1
from 8-K/A 109 pages [***] Certain Information in This Exhibit Has Been Omitted Because It Is Permitted to Be Omitted by Applicable Regulatory Guidance
12/34/56
EX-10.2
from 10-Q 3 pages [***] Certain Information in This Exhibit Has Been Omitted Because It Is Permitted to Be Omitted by Applicable Regulatory Guidance. Amendment No. 2 to Exclusive License and Commercialization Agreement
12/34/56
EX-10.40
from 10-K 25 pages Exclusive Product License Agreement
12/34/56
EX-10
from 10-K 5 pages [***] Certain Information in This Exhibit Has Been Omitted Because It Is Permitted to Be Omitted by Applicable Regulatory Guidance
12/34/56
EX-10.2
from 10-Q 4 pages Coherus Biosciences, Inc. ​ Common Stock Amendment No. 2 to Sales Agreement
12/34/56
EX-10.1
from 10-Q 21 pages [***] Certain Information in This Exhibit Has Been Omitted Because It Is Permitted to Be Omitted by Applicable Regulatory Guidance
12/34/56
EX-10.1
from 10-Q 3 pages Coherus Biosciences, Inc. ​ Common Stock Amendment No. 1 to Sales Agreement
12/34/56
EX-10.3
from 10-Q 6 pages [***] Certain Information in This Exhibit Has Been Omitted Because It Is Permitted to Be Omitted by Applicable Regulatory Guidance
12/34/56
EX-10.2
from 10-Q 15 pages Coherus Biosciences, Inc. Executive Change in Control and Severance Plan (And Summary Plan Description) Effective January 1, 2023
12/34/56
EX-10.1
from 10-Q 26 pages [***] Certain Information in This Exhibit Has Been Omitted Because It Is Permitted to Be Omitted by Applicable Regulatory Guidance
12/34/56
EX-10.25
from 10-K 20 pages [***] Certain Information in This Exhibit Has Been Omitted Because It Is Permitted to Be Omitted by Applicable Regulatory Guidance
12/34/56
EX-10.1
from 10-Q 7 pages Agreement
12/34/56
EX-10.1
from 10-Q 7 pages [***] Certain Information in This Exhibit Has Been Omitted Because It Is Permitted to Be Omitted by Applicable Regulatory Guidance
12/34/56
EX-10.32
from 10-K 8 pages [***] Certain Information in This Exhibit Has Been Omitted Because It Is Permitted to Be Omitted by Applicable Regulatory Guidance. ​
12/34/56
EX-10.1
from 8-K 109 pages [***] Certain Information in This Exhibit Has Been Omitted Because It Is Permitted to Be Omitted by Applicable Regulatory Guidance
12/34/56
EX-10.2
from 10-Q 23 pages Agreement
12/34/56